CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

IMM-101Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1660 Observation Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.

NCT04442048 Cancer Covid-19 Biological: IMM-101 Other: Observation
MeSH:Infection

Primary Outcomes

Description: WHO definition of "influenza-like illness" (ILI) [Fitzner 2018] or confirmed viral/bacterial respiratory infection AND Results in a change or delay in cancer treatment or requirement for and unscheduled medical assesment, hospitalization or death.

Measure: The rate of "flu-like illness" which includes:

Time: 1 year

Secondary Outcomes

Measure: The incidence of documented COVID-19 infection (confirmed by any Health Canada approved COVID-19 test. Both symptomatic and asymptomatic infections will be documented

Time: 1 year

Measure: The rate of severe respiratory and COVID-19 infection defined as a confirmed COVID-19 infection leading to hospitalization, ICU admission or death

Time: 1 year

Measure: The number of events that meet the definition of the primary endpoint, as measured within the one-year follow-up (patients may meet the primary endpoint more than once and be counted multiple times).

Time: 1 year

Measure: The incidence of COVID-19 seroconverted patients between baseline, 3 months, 6 months and 12 months

Time: 3, 6, and 12 months

Measure: The incremental cost-effectiveness ratio (in the unit of CAD$ per life-years gained) measured with EQ-5D-5L

Time: 1 year

Measure: Failure-free survival, as time from enrollment to recurrence or progression declared by the investigator on the basis of objective standard evaluation consistent with the disease site or death

Time: 1 year

Measure: Overall survival (OS), as time from enrollment to death from any cause

Time: 1 year

Measure: Incidence, frequency, and severity of AEs considered possibly, probably or definitely related to receipt of IMM-101

Time: 1 year

Measure: Incidence and frequency of local injection site reactions subsequent to IMM-101 administration

Time: 1 year

Measure: Incidence and duration of ICU admission related to documented COVID-19 infection

Time: 1 year

No related HPO nodes (Using clinical trials)